Human Genome Sciences (NASDAQ: HGSI) is a biopharmaceutical corporation founded in 1992. It uses the human DNA sequence to develop protein and antibody drugs. As of 2008, it has drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. It collaborates with other biotechnology and pharmaceutical companies, for development partnerships and licensing.
Benly...
More
Human Genome Sciences (NASDAQ: HGSI) is a biopharmaceutical corporation founded in 1992. It uses the human DNA sequence to develop protein and antibody drugs. As of 2008, it has drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. It collaborates with other biotechnology and pharmaceutical companies, for development partnerships and licensing.
Benlysta (belimumab) received U.S. Food and Regulatory Administration approval for use in lupus in March 2011. Belimumab is being developed with Glaxo SmithKline, Abthrax (raxibacumab) for anthrax disease is the subject of a contract with the US Government under Project BioShield. Development of Albuferon (albinterferon) for Hepatitis C has been discontinued after fatalities during early testing.
The company was founded by William A. Haseltine, a noted Harvard professor and AIDS researcher. HGS had a partnership for several years after its founding...
Less
